title: Daily cocaine self-administration under long-access conditions augments restraint-induced increases in plasma corticosterone and impairs glucocorticoid receptor-mediated negative feedback in rats.
abstract: Cocaine addiction appears to be associated with a drug-induced dysregulation of stressor responsiveness that may contribute to further cocaine use. The present study examined alterations in stressor-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis in rats provided daily access to cocaine for self-administration (SA) under long-access conditions (1.0 mg/kg/infusion; 6 hx14 days). Cocaine self-administering rats displayed reduced basal plasma corticosterone (CORT) levels but showed an augmented restraint-induced percent increase response from baseline compared to saline self-administering controls when measured 24 days after SA testing. This augmented CORT response may have been attributable to impaired glucocorticoid receptor (GR)-mediated feedback regulation of HPA function, since cocaine self-administering rats were also less susceptible to dexamethasone (0.01 mg/kg, i.p.) suppression of plasma CORT levels. GR protein expression measured using Western blot analysis was significantly reduced in the dorsomedial hypothalamus (including the paraventricular nucleus [PVN]) but not in the pituitary gland, ventromedial hypothalamus, dorsal hippocampus, ventral subiculum, medial prefrontal cortex or amygdala in cocaine self-administering rats. Surprisingly, basal corticotropin-releasing hormone (CRH) mRNA or post-restraint increases in CRH mRNA measured at a single (90 min) time-point in the PVN using in situ hybridization did not differ between groups. The findings suggest that cocaine use produces persistent changes in individual responsiveness to stressors that may contribute to the addiction process.
authors: Department of Biomedical Sciences, Box 1881, Marquette University, Milwaukee, WI 53201-1881, USA. john.mantsch@marquette.edu
authors: John R
authors: JR
authors: Mantsch
authors: William E
authors: WE
authors: Cullinan
authors: Lee C
authors: LC
authors: Tang
authors: David A
authors: DA
authors: Baker
authors: Eric S
authors: ES
authors: Katz
authors: Michael A
authors: MA
authors: Hoks
authors: Dana R
authors: DR
authors: Ziegler
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002908:Chronic Disease; D003042:Cocaine / Q000009:adverse effects; D019970:Cocaine-Related Disorders / Q000097:blood* / Q000503:physiopathology*; D003345:Corticosterone / Q000097:blood* / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000235:genetics; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects; D004334:Drug Administration Schedule; D025461:Feedback, Physiological / Q000187:drug effects / Q000502:physiology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000187:drug effects* / Q000378:metabolism; D012149:Restraint, Physical / Q000009:adverse effects; D012646:Self Administration; D013315:Stress, Psychological / Q000097:blood* / Q000503:physiopathology*; D013995:Time
chemical_list: D018765:Dopamine Uptake Inhibitors; D012333:RNA, Messenger; D011965:Receptors, Glucocorticoid; D003346:Corticotropin-Releasing Hormone; D003042:Cocaine; D003345:Corticosterone
references: Eur J Pharmacol. 2000 Jan 3;387(1):59-62
references: 10633161
references: Behav Pharmacol. 1999 Sep;10(5):523-9
references: 10780258
references: J Pharmacol Exp Ther. 2000 Jul;294(1):239-47
references: 10871318
references: Psychopharmacology (Berl). 2001 Mar;154(3):311-8
references: 11351938
references: Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):71-82
references: 11750770
references: Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):83-97
references: 11750771
references: Psychopharmacology (Berl). 2001 Dec;158(4):343-59
references: 11797055
references: Psychopharmacology (Berl). 2001 Dec;158(4):374-81
references: 11797058
references: Neuropsychopharmacology. 2002 Mar;26(3):286-94
references: 11850143
references: J Pharmacol Exp Ther. 2002 Jun;301(3):785-9
references: 12023504
references: Brain Res. 2003 Feb 28;964(2):187-99
references: 12576179
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):177-83
references: 12652344
references: Psychopharmacology (Berl). 2003 Jul;168(1-2):170-6
references: 12845419
references: Psychoneuroendocrinology. 2003 Oct;28(7):836-62
references: 12892653
references: Neuroendocrinology. 2003 Sep;78(3):154-62
references: 14512708
references: Psychopharmacol Bull. 2003 Summer;37(3):84-9
references: 14608241
references: Psychopharmacology (Berl). 2004 Aug;175(1):26-36
references: 15042275
references: Endocrinology. 1965 Aug;77(2):406-8
references: 4284417
references: Nature. 1970 Aug 15;227(5259):680-5
references: 5432063
references: Proc Natl Acad Sci U S A. 1983 Nov;80(22):6982-6
references: 6316340
references: Am J Physiol. 1985 Nov;249(5 Pt 2):R527-32
references: 2998210
references: Brain Res. 1987 Oct 6;422(2):403-6
references: 2823980
references: Peptides. 1987 Sep-Oct;8(5):819-22
references: 2829143
references: Am J Psychiatry. 1988 Sep;145(9):1094-8
references: 3414852
references: Anal Biochem. 1988 Nov 15;175(1):231-7
references: 3245570
references: Brain Res. 1991 Mar 15;543(2):301-6
references: 1647834
references: Mol Endocrinol. 1992 Jul;6(7):1061-9
references: 1324419
references: Life Sci. 1992;51(12):887-97
references: 1325586
references: Brain Res. 1992 Aug 28;589(1):154-6
references: 1330207
references: J Pharmacol Exp Ther. 1992 Nov;263(2):505-9
references: 1331401
references: Horm Res. 1992;37(6):221-4
references: 1338055
references: Psychopharmacology (Berl). 1994 Jan;113(3-4):547-54
references: 7862874
references: Eur J Pharmacol. 1995 Oct 24;285(3):317-21
references: 8575521
references: Biol Psychiatry. 1995 Dec 1;38(11):751-5
references: 8580229
references: J Pharmacol Exp Ther. 1996 Apr;277(1):225-34
references: 8613924
references: J Pharmacol Exp Ther. 1996 Sep;278(3):1195-200
references: 8819502
references: J Pharmacol Exp Ther. 1996 Oct;279(1):351-8
references: 8859013
references: Neuroendocrinology. 1996 Nov;64(5):337-48
references: 8930934
references: J Pharmacol Exp Ther. 1997 Jun;281(3):1401-7
references: 9190876
references: Brain Res. 1998 Mar 30;788(1-2):305-10
references: 9555067
references: J Neurosci. 1998 Jul 15;18(14):5529-36
references: 9651233
references: J Pharmacol Exp Ther. 1998 Oct;287(1):72-80
references: 9765324
references: Science. 1998 Oct 9;282(5387):298-300
references: 9765157
references: Neuroendocrinology. 1998 Nov;68(5):334-44
references: 9822801
references: J Pharmacol Exp Ther. 1999 Jul;290(1):393-402
references: 10381805
references: Psychoneuroendocrinology. 2005 Oct;30(9):880-91
references: 15975729
references: Endocrinology. 2005 Dec;146(12):5587-95
references: 16150912
references: Neuropsychopharmacology. 2006 Mar;31(3):563-71
references: 16034440
references: Arch Gen Psychiatry. 2006 Mar;63(3):324-31
references: 16520439
references: Psychopharmacology (Berl). 2006 Jul;187(1):60-7
references: 16598453
references: Neuropsychopharmacology. 2007 Feb;32(2):367-76
references: 16641943
references: Neurosci Lett. 2007 Mar 30;415(3):269-73
references: 17293045